LDL Cholesterol Calculator

What is LDL Cholesterol?

LDL (Low-Density Lipoprotein) cholesterol is often called "bad cholesterol" because elevated levels are strongly associated with the development of atherosclerosis — the buildup of fatty plaques in the walls of arteries. This process can lead to coronary heart disease, stroke, and peripheral arterial disease. LDL particles carry cholesterol from the liver to the tissues and arteries, and when present in excess, they can infiltrate the arterial wall, triggering an inflammatory response that forms atherosclerotic plaques.

Cholesterol is a waxy, fat-like substance that is essential for life. It is a component of cell membranes, a precursor for steroid hormones (cortisol, estrogen, testosterone), bile acids, and vitamin D. The liver produces approximately 80% of the body's cholesterol, while the remaining 20% comes from dietary sources. Because cholesterol is not water-soluble, it must be transported through the bloodstream within lipoproteins — protein-coated particles that make fat transport possible.

LDL cholesterol has been established as a causal factor in atherosclerotic cardiovascular disease (ASCVD) through decades of epidemiological studies, genetic research (Mendelian randomization studies), and clinical trials. The relationship between LDL cholesterol and cardiovascular risk is log-linear: every 38.67 mg/dL (1 mmol/L) reduction in LDL cholesterol reduces cardiovascular events by approximately 22%. This has made LDL the primary target of lipid-lowering therapy worldwide.

The Friedewald Equation

The Friedewald equation, published by William Friedewald and colleagues in 1972 in the journal Clinical Chemistry, remains the most widely used method for estimating LDL cholesterol from a standard fasting lipid panel. Rather than measuring LDL directly (which is more expensive and technically demanding), the equation calculates LDL from three readily available measurements.

The formula is based on the principle that total cholesterol equals the sum of LDL, HDL, and VLDL cholesterol. Since VLDL cholesterol is not routinely measured, Friedewald's key insight was that VLDL cholesterol can be estimated as triglycerides divided by 5 (in mg/dL units). This approximation holds because, in fasting samples, most triglycerides are carried in VLDL particles, and the cholesterol content of VLDL is approximately one-fifth of the triglyceride concentration.

While the Friedewald equation has served clinical medicine well for over 50 years, it has known limitations. In 2020, Martin, Hopkins, and colleagues developed an improved equation (the Martin/Hopkins method) that uses adjustable triglyceride-to-VLDL ratios based on a patient's specific triglyceride and non-HDL cholesterol levels. This newer method is more accurate across a wider range of triglyceride values but is computationally more complex.

Cholesterol Types Explained

The standard lipid panel measures four components, each playing a distinct role in cardiovascular health:

• LDL (Low-Density Lipoprotein): The "bad" cholesterol. Carries cholesterol to the arteries. Higher levels increase cardiovascular risk. LDL particles can be further classified by size and density — small, dense LDL particles are considered more atherogenic than large, buoyant particles.
• HDL (High-Density Lipoprotein): The "good" cholesterol. Performs reverse cholesterol transport — carrying cholesterol away from the arteries back to the liver for recycling or excretion. Higher HDL levels are generally protective against cardiovascular disease. HDL also has anti-inflammatory and antioxidant properties.
• VLDL (Very Low-Density Lipoprotein): Produced by the liver to transport triglycerides to tissues. VLDL particles are converted to intermediate-density lipoproteins (IDL) and eventually to LDL particles in the bloodstream. Elevated VLDL indicates increased triglyceride production.
• Triglycerides: Not technically cholesterol, but a type of fat (lipid) in the blood. The body converts excess calories, alcohol, and sugar into triglycerides, which are stored in fat cells. Elevated triglycerides are an independent risk factor for cardiovascular disease and are associated with insulin resistance, metabolic syndrome, and pancreatitis (when extremely elevated).
• Non-HDL Cholesterol: Calculated as Total Cholesterol minus HDL. This measure captures all atherogenic lipoproteins (LDL, VLDL, IDL, and lipoprotein(a)) in a single number. Many guidelines now consider non-HDL cholesterol a better predictor of cardiovascular risk than LDL alone, especially in patients with elevated triglycerides.

Optimal Cholesterol Levels

Lipid	Optimal	Near Optimal / Desirable	Borderline High	High	Very High
LDL	< 100	100 – 129	130 – 159	160 – 189	≥ 190
Total Cholesterol	< 200	—	200 – 239	≥ 240	—
HDL	≥ 60 (protective)	40 – 59	—	< 40 (risk factor)	—
Triglycerides	< 150	150 – 199	200 – 499	≥ 500	—
Non-HDL	< 130	130 – 159	160 – 189	190 – 219	≥ 220

All values are in mg/dL. For patients at very high cardiovascular risk (previous heart attack, established cardiovascular disease), even lower LDL targets may be appropriate. Current guidelines (2018 ACC/AHA) recommend LDL <70 mg/dL for high-risk patients and consideration of <55 mg/dL for very high-risk patients, consistent with European (ESC/EAS 2019) guidelines.

Heart Disease Risk

Elevated LDL cholesterol is one of the most important modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD). The relationship between LDL and heart disease has been demonstrated across multiple lines of evidence:

• Epidemiological Studies: Populations with higher average LDL levels have higher rates of coronary heart disease. The Framingham Heart Study, started in 1948, was instrumental in establishing this association.
• Genetic Studies: People with familial hypercholesterolemia (genetic mutations causing very high LDL) develop premature atherosclerosis and heart attacks. Conversely, genetic variants that naturally lower LDL (such as PCSK9 loss-of-function mutations) are associated with dramatically reduced cardiovascular risk.
• Clinical Trials: Statin trials involving over 170,000 patients have demonstrated that every 38.67 mg/dL reduction in LDL cholesterol reduces major vascular events by approximately 22%, regardless of baseline LDL level.
• Imaging Studies: Coronary calcium scoring and coronary CTA studies show that plaque burden correlates with cumulative LDL exposure over a lifetime, supporting the "lower for longer" hypothesis.

The TC/HDL ratio is another useful metric. A ratio below 3.5 is considered ideal, 3.5–5.0 is average, and above 5.0 indicates increased cardiovascular risk. This ratio captures the balance between atherogenic and protective lipoproteins in a single number.

How to Lower LDL

Lifestyle Modifications

• Dietary Changes: Reduce saturated fat intake to less than 7% of total calories. Replace saturated fats with unsaturated fats (olive oil, nuts, avocados). Increase soluble fiber intake (oats, beans, lentils, fruits) — 5–10 grams of soluble fiber daily can reduce LDL by 5–10%. Incorporate plant sterols/stanols (2 g/day reduces LDL by 6–15%).
• Exercise: Regular aerobic exercise (150 minutes/week of moderate intensity) can lower LDL by 5–10% and raise HDL by 3–6%. Exercise also improves LDL particle size, shifting from small dense to large buoyant particles.
• Weight Loss: Losing 5–10% of body weight can reduce LDL by 5–8%, lower triglycerides by 20–30%, and raise HDL by 5–10%.
• Smoking Cessation: Quitting smoking improves HDL cholesterol by an average of 5–10% and reduces overall cardiovascular risk.
• Limit Alcohol: Moderate alcohol consumption may raise HDL, but excessive intake raises triglycerides and overall cardiovascular risk.

Medications

• Statins: First-line therapy. High-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) reduce LDL by 50% or more. The most extensively studied cardiovascular drugs with proven mortality benefit.
• Ezetimibe: Blocks cholesterol absorption in the gut. Reduces LDL by an additional 15–20% when added to a statin. The IMPROVE-IT trial demonstrated incremental benefit.
• PCSK9 Inhibitors: Injectable monoclonal antibodies (evolocumab, alirocumab) that reduce LDL by 50–60% on top of statin therapy. Reserved for patients with familial hypercholesterolemia or those who cannot reach targets with statins alone.
• Bempedoic Acid: An oral ACL inhibitor that reduces LDL by approximately 18%. Can be used in patients intolerant to statins.
• Inclisiran: A small interfering RNA (siRNA) targeting PCSK9 synthesis. Administered by injection twice yearly. Reduces LDL by approximately 50%.
• Bile Acid Sequestrants: (Cholestyramine, colesevelam) reduce LDL by 15–25% but can raise triglycerides and cause gastrointestinal side effects.

Limitations (TG > 400)

The fundamental assumption of the Friedewald equation — that VLDL cholesterol equals triglycerides divided by 5 — breaks down under several conditions:

• Triglycerides > 400 mg/dL: At high triglyceride levels, the TG/5 approximation significantly overestimates VLDL cholesterol, leading to underestimation of LDL. The equation should not be used when TG exceeds 400 mg/dL.
• Type III Hyperlipoproteinemia: Patients with dysbetalipoproteinemia have abnormal VLDL particles (beta-VLDL) with a different cholesterol-to-triglyceride ratio, making the equation inaccurate.
• Non-Fasting Samples: The Friedewald equation was developed for fasting samples. Postprandial triglyceride elevation can cause inaccurate results, though modern guidelines increasingly accept non-fasting lipid panels for screening.
• Very Low LDL Levels: When calculated LDL is very low (<70 mg/dL), the Friedewald equation tends to overestimate LDL compared to direct measurement. This can lead to overtreatment in some patients.

For patients with elevated triglycerides, the Martin/Hopkins equation provides improved accuracy by using adjustable TG:VLDL-C ratios derived from a database of over 1.3 million lipid profiles. Direct LDL measurement by ultracentrifugation or chemical analysis remains the gold standard when accuracy is critical.

Cholesterol Diagram

Frequently Asked Questions

What is a normal LDL cholesterol level?

An LDL below 100 mg/dL is considered optimal for most adults. However, target LDL levels depend on your overall cardiovascular risk. For patients with established cardiovascular disease, diabetes, or multiple risk factors, guidelines recommend LDL below 70 mg/dL. For very high-risk patients (recent heart attack, diabetes plus multiple risk factors), some guidelines target LDL below 55 mg/dL.

Do I need to fast before a cholesterol test?

Traditionally, a 9–12 hour fast was required for accurate lipid panel results. However, recent evidence and updated guidelines from major cardiology organizations indicate that non-fasting lipid panels are acceptable for cardiovascular risk screening. Triglycerides and calculated LDL may be slightly affected by a recent meal, but the clinical impact is minimal for most patients. Fasting is still recommended when triglycerides are elevated or when precise LDL calculation is needed for treatment decisions.

Why is the Friedewald equation inaccurate with high triglycerides?

The Friedewald equation estimates VLDL cholesterol as triglycerides divided by 5, based on the observation that the average triglyceride-to-VLDL-cholesterol ratio is approximately 5:1 in fasting samples. However, this ratio varies with triglyceride levels. At triglycerides above 400 mg/dL, VLDL particles become triglyceride-enriched, and the actual TG:VLDL ratio can be 8:1 or higher. This means the equation overestimates VLDL cholesterol and consequently underestimates LDL cholesterol, potentially leading to under-treatment of hyperlipidemia.

What is the TC/HDL ratio and why does it matter?

The Total Cholesterol to HDL ratio (TC/HDL) provides a snapshot of your overall cholesterol balance. It is calculated by dividing total cholesterol by HDL cholesterol. A ratio below 3.5 is considered ideal, 3.5–5.0 is average risk, and above 5.0 indicates elevated cardiovascular risk. Some studies suggest the TC/HDL ratio is a better predictor of heart disease than LDL alone because it captures both the atherogenic (LDL + VLDL) and protective (HDL) components in a single metric.

Can cholesterol be too low?

Very low LDL cholesterol (below 40 mg/dL) occurs naturally in some individuals and in patients taking potent lipid-lowering therapy. Large clinical trials (FOURIER, ODYSSEY Outcomes) have not shown adverse effects from achieving very low LDL levels with medication. However, extremely low total cholesterol has been associated in some observational studies with increased risk of hemorrhagic stroke and certain cancers, though causation has not been established. Most experts agree that the benefits of lowering LDL outweigh potential risks for patients with established cardiovascular disease.

How often should cholesterol be checked?

The AHA recommends cholesterol screening every 4–6 years for adults aged 20 and older with average risk. For patients on lipid-lowering therapy, levels should be checked 4–12 weeks after starting or adjusting medication, then every 3–12 months. Patients with elevated cardiovascular risk, diabetes, or family history of premature heart disease should be screened more frequently, typically annually.